Related references
Note: Only part of the references are listed.Intention-to-Treat Survival Benefit of Liver Transplantation in Patients With Hepatocellular Cancer
Quirino Lai et al.
HEPATOLOGY (2017)
Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2017)
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
Riad Salem et al.
GASTROENTEROLOGY (2016)
Surrogate End Points and Their Validation in Oncology Clinical Trials
Fengmin Zhao
JOURNAL OF CLINICAL ONCOLOGY (2016)
Types of Research Bias Encountered in IR
Ahmed Gabr et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2016)
Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach
Vania Tacher et al.
RADIOLOGY (2016)
Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma
Adeel R. Seyal et al.
HEPATOLOGY (2015)
The Global Burden of Cancer 2013 Global Burden of Disease Cancer Collaboration
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2015)
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
Bruno Vincenzi et al.
PLOS ONE (2015)
Challenges of Guarantee-Time Bias
Anita Giobbie-Hurder et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization
MingDe Lin et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2012)
Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times
Khairuddin Memon et al.
GASTROENTEROLOGY (2011)
Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
Riad Salem et al.
GASTROENTEROLOGY (2011)
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation
Ahsun Riaz et al.
JOURNAL OF HEPATOLOGY (2011)
Research Reporting Standards for Radioembolization of Hepatic Malignancies
Riad Salem et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2011)
Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes
Riad Salem et al.
GASTROENTEROLOGY (2010)
Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma
Ahsun Riaz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort
Robert J. Lewandowski et al.
RADIOLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization
R. J. Lewandowski et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Evaluation of Tumor Response After Locoregional Therapies in Hepatocellular Carcinoma Are Response Evaluation Criteria in Solid Tumors Reliable?
Alejandro Forner et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
Sean F. Altekruse et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables
James R. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Surrogate endpoint validation: statistical elegance versus clinical relevance
E. M. Green et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2008)
Safety and efficacy of Y-90 radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis
Laura M. Kulik et al.
HEPATOLOGY (2008)
Radioembolization with 90Yttrium microspheres:: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 1:: Technical and methodologic considerations
Riad Salem et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2006)
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma
Gerd Otto et al.
LIVER TRANSPLANTATION (2006)
Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization
YK Maddala et al.
LIVER TRANSPLANTATION (2004)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial
JM Llovet et al.
LANCET (2002)
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
CM Lo et al.
HEPATOLOGY (2002)
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
J Bruix et al.
JOURNAL OF HEPATOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
